Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome (Ipsen, 043914)
- Development stage
- Approved
- Lead developer
- Ipsen
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Irinotecan liposome (Onivyde) is a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan. Developed to improve the pharmacokinetic profile and tumor-specific delivery of irinotecan and its active metabolite, SN-38, the liposomal encapsulation protects the drug from premature metabolism and allows for prolonged circulation and preferential accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. It was first approved by the FDA in 2015 for use in combination with 5-fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy. More recently, it has been approved as a first-line treatment for metastatic pancreatic adenocarcinoma in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX). It is also under investigation for other solid tumors, including biliary tract cancer and small cell lung cancer.
- Brand names
- Onivyde
- Other names
- nanoliposomal irinotecannal-IRIliposomal irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposome (Ipsen, 043914).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome (Ipsen, 043914).